肿瘤预防与治疗Issue(3)：130-133,4.DOI:10.3969/j.issn.1674-0904.2014.03.004
两种方案治疗广泛期小细胞肺癌的临床观察
Clinical Analysis of Two Chemotherapy Regimens for Patients with Extensive Small-cell Lung Cancer
张容榕 1林琳 1刘爱学 1冯天举1
作者信息
- 1. 深圳市第二人民医院肿瘤科，广东 深圳 518035
- 折叠
摘要
Abstract
Objective: To compare and analyze the efficacy and safety of two different treatment schema in previ-ously untreated extensive small-cell lung cancer. Methods:Seventy cases of patients with extensive small-cell lung cancer treated in the Oncology Department of our hospital from January 2010 to January 2013 were randomly assigned into irinote-can group( IP group,35 cases) and VP-16 group( EP group,35 cases) by random number table . Patients in IP group were treated with irinotecan and cisplatin(IP)and in EP group were treated with VP-16 and cisplatin(EP). The treatment re-sponse was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) (version 1. 1). Patients were assessed for toxicity according to WHO criteria for adverse events. Results:The objective response rates( RR) of IP group and EP group were 74. 28% and 71. 42%,respectively(P>0. 05). The median progression-free survival(PFS) for IP group and EP group were 4. 3 and 3. 7 months respectively(P>0. 05). The overall survival(OS) for IP group and EP group was 9. 3 and 8. 9 months,respectively(P>0. 05). The common adverse effects of IP group inclucled neutropenia(54. 29%),throm-bocytopenia(14. 29%),anemia(25. 71%),diarrhea(22. 86%)and nausea(71. 43%). The common adverse effects of EP group included neutropenia(80. 0%),thrombocytopenia(60. 0%),anemia(54. 29%),diarrhea(2. 86%)and nausea(74. 29%) . Conclusion:The study shows that there is no significant difference with the efficacy and survival of IP and EP regi-men as the first-line therapy for extensive small-cell lung cancer and the adverse effects are tolerant.关键词
广泛期/小细胞肺癌/伊立替康/VP-16/顺铂/近期疗效/毒副反应Key words
Extensive Stage/Small-cell Lung Cancer/Irinotecan/VP-16/Cisplatin/Curative Effect/Adverse Effect分类
医药卫生引用本文复制引用
张容榕,林琳,刘爱学,冯天举..两种方案治疗广泛期小细胞肺癌的临床观察[J].肿瘤预防与治疗,2014,(3):130-133,4.
